| Blood-brain barrier breakdown in the aging human hippocampus A Montagne, SR Barnes, MD Sweeney, MR Halliday, AP Sagare, Z Zhao, ... Neuron 85 (2), 296-302, 2015 | 1963 | 2015 |
| Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction DA Nation, MD Sweeney, A Montagne, AP Sagare, LM D’Orazio, ... Nature medicine 25 (2), 270-276, 2019 | 1276 | 2019 |
| APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline A Montagne, DA Nation, AP Sagare, G Barisano, MD Sweeney, ... Nature 581 (7806), 71-76, 2020 | 961 | 2020 |
| The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies G Hsich, K Kenney, CJ Gibbs Jr, KH Lee, MG Harrington New England Journal of Medicine 335 (13), 924-930, 1996 | 904 | 1996 |
| Methods for increasing the resolution of two-dimensional protein electrophoresis DF Hochstrasser, MG Harrington, AC Hochstrasser, MJ Miller, CR Merril Analytical biochemistry 173 (2), 424-435, 1988 | 773 | 1988 |
| Vascular dysfunction—the disregarded partner of Alzheimer's disease MD Sweeney, A Montagne, AP Sagare, DA Nation, LS Schneider, ... Alzheimer's & Dementia 15 (1), 158-167, 2019 | 607 | 2019 |
| Free amino acid and dipeptide changes in the body fluids from Alzheimer’s disease subjects AN Fonteh, RJ Harrington, A Tsai, P Liao, MG Harrington Amino acids 32, 213-224, 2007 | 295 | 2007 |
| Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease MG Harrington, CR Merril, DM Asher, DC Gajdusek New England Journal of Medicine 315 (5), 279-283, 1986 | 205 | 1986 |
| Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease T Sunderland, CR Merril, MG Harrington, BA Lawlor, SE Molchan, ... The Lancet 334 (8662), 570, 1989 | 200 | 1989 |
| No-reflow phenomenon in the heart and brain RA Kloner, KS King, MG Harrington American Journal of Physiology-Heart and Circulatory Physiology 315 (3 …, 2018 | 199 | 2018 |
| Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges AF Hühmer, RG Biringer, H Amato, AN Fonteh, MG Harrington Disease markers 22 (1-2), 3-26, 2006 | 189 | 2006 |
| Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E ε4 carriers: a review HN Yassine, MN Braskie, WJ Mack, KJ Castor, AN Fonteh, LS Schneider, ... JAMA neurology 74 (3), 339-347, 2017 | 177 | 2017 |
| White matter lipids as a ketogenic fuel supply in aging female brain: implications for Alzheimer's disease LP Klosinski, J Yao, F Yin, AN Fonteh, MG Harrington, TA Christensen, ... EBioMedicine 2 (12), 1888-1904, 2015 | 157 | 2015 |
| Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods AN Fonteh, RJ Harrington, AF Huhmer, RG Biringer, JN Riggins, ... Disease markers 22 (1-2), 39-64, 2006 | 144 | 2006 |
| Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's disease AN Fonteh, M Cipolla, J Chiang, X Arakaki, MG Harrington PloS one 9 (6), e100519, 2014 | 130 | 2014 |
| Cerebrospinal-fluid test for new-variant Creutzfeldt-Jakob disease RG Will, M Zeidler, P Brown, M Harrington, KH Lee, KL Kenney The Lancet 348 (9032), 955, 1996 | 127 | 1996 |
| ApoE4 alters ABCA1 membrane trafficking in astrocytes V Rawat, S Wang, J Sima, R Bar, O Liraz, U Gundimeda, T Parekh, ... Journal of Neuroscience 39 (48), 9611-9622, 2019 | 125 | 2019 |
| Regenerable and simultaneous surface plasmon resonance detection of aβ (1− 40) and aβ (1− 42) peptides in cerebrospinal fluids with signal amplification by streptavidin … N Xia, L Liu, MG Harrington, J Wang, F Zhou Analytical chemistry 82 (24), 10151-10157, 2010 | 125 | 2010 |
| Executive function changes before memory in preclinical Alzheimer’s pathology: a prospective, cross-sectional, case control study MG Harrington, J Chiang, JM Pogoda, M Gomez, K Thomas, SDB Marion, ... PloS one 8 (11), e79378, 2013 | 120 | 2013 |
| Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel C Babiloni, X Arakaki, H Azami, K Bennys, K Blinowska, L Bonanni, ... Alzheimer's & Dementia 17 (9), 1528-1553, 2021 | 111 | 2021 |
